Center for Research in Security Prices, LLC

Black patients with TNBC received immunotherapy less often than white patients, but outcomes were similar when treated. Socioeconomic factors were main barriers for Black patients, while Medicare enrollees and those in community programs had lower immunotherapy rates. Immunotherapy mitigated racial survival differences in metastatic TNBC.

Black patients with triple-negative breast cancer (TNBC) receive immunotherapy at lower rates than white patients, with socioeconomic factors identified as barriers. Despite this, when Black patients do receive immunotherapy, their survival rates are similar to white patients, suggesting immunotherapy could mitigate racial disparities in TNBC outcomes.

HotSpot Therapeutics appoints Dr. Alison O'Neill as Chief Medical Officer, leveraging her extensive biopharmaceutical experience to advance their pipeline of allosteric drug candidates for cancer and autoimmune diseases.

AstraZeneca's Imfinzi in bladder cancer reduced death risk by 25%; Merck and Eisai's combo in liver cancer cut progression or death risk by a third; Bristol's lung cancer approach faced criticism for 'cherry-picking' subgroups.

Students participated in the 23rd Festival of Science, Technology, and Art in Łódź and organized workshops. Two research projects were published in Web of Science-indexed journals: one on endophytic bacteria from stinging nettle and another on bacterial regulatory proteins. inż. Jakub Filipek received a Fulbright scholarship for a research internship in the U.S., following inż. Aleksandra Kośmider's footsteps.

The 2024 NIDA International Forum, held in Montreal, featured over 200 attendees from 73 countries, focusing on addiction research, treatment, and policy. Key sessions included updates on NIDA's strategic priorities, discussions on drug policy reforms, medical cannabis education, opioid stigma in pharmacies, and real-world interventions. The event also highlighted international research collaborations and the importance of addressing substance use in humanitarian settings.

Geron Corporation appoints Jim Ziegler as Executive VP, Chief Commercial Officer to lead global commercial strategy and drive growth of RYTELO™, effective September 9, 2024.

Ritik Shah, ’27, returned to UChicago Law School after earning a master’s in biotechnology, aiming to bridge science and non-science sectors through law. He organized Model UN conferences and took science communication classes as an undergrad, shaping his interest in bridging the science-public gap. His hobbies include art and music, and he looks forward to learning from diverse law school classmates.